| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 150, Issue 9 3924-3931, Copyright © 1993 by American Association of Immunologists
ARTICLES |
FP Heinzel, RM Rerko, F Hatam and RM Locksley
Veterans Administration Medical Center, Cleveland, OH 44106.
BALB/c mice are highly susceptible to disseminated infection with the intracellular protozoa Leishmania major. Progression of disease requires in vivo expansion of Th2 CD4+ lymphocytes and is reversed by treatment with anti-IL-4 monoclonal antibody. Inasmuch as IL-2 may be necessary for both the production of IL-4 and differentiation of Th2 cells, the possible contribution of IL-2 to progressive infection was examined. Four weekly injections of anti-IL-2 mAb (S4B6) cured more than 80% of BALB/c mice infected with L. major, as determined by diminished footpad swelling and decreased numbers of parasites in infected tissues. Multiple doses of S4B6 were necessary for benefit; a single dose given at the time of infection was ineffective. The anti-IL- 2R mAb PC61 demonstrated a similar protective effect when administered twice weekly for 4 wk. Anti-IL-2-mediated cure of cutaneous leishmaniasis was associated with increased IFN-gamma and decreased IL- 4 production by regional lymph node cells compared to untreated BALB/c mice with progressive illness. Both CD4+ and CD8+ T lymphocytes contributed to the increased expression of IFN-gamma mRNA in cured mice. These data suggest that levels of IL-2 suboptimal for Th2 expansion in vivo do not inhibit Th1 CD4+ and CD8+ T cell activation and IFN-gamma synthesis. Other cytokines or activation pathways that are either IL-2-independent or synergistic with low levels of IL-2 may account for the appearance of curative T cell responses during treatment with anti-IL-2 antibodies.
This article has been cited by other articles:
|
|
 |
|
  M. Bodas, N. Jain, A. Awasthi, S. Martin, R. K. Penke Loka, D. Dandekar, D. Mitra, and B. Saha Inhibition of IL-2 Induced IL-10 Production as a Principle of Phase-Specific Immunotherapy J. Immunol., October 1, 2006; 177(7): 4636 - 4643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Suffia*, S. K. Reckling*, G. Salay*, and Y. Belkaid* A Role for CD103 in the Retention of CD4+CD25+ Treg and Control of Leishmania major Infection J. Immunol., May 1, 2005; 174(9): 5444 - 5455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Marsland, T. J. Soos, G. Spath, D. R. Littman, and M. Kopf Protein Kinase C {theta} Is Critical for the Development of In Vivo T Helper (Th)2 Cell But Not Th1 Cell Responses J. Exp. Med., July 19, 2004; 200(2): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, U. M. Padigel, P. Scott, and J. P. Farrell Combined Treatment with Interleukin-12 and Indomethacin Promotes Increased Resistance in BALB/c Mice with Established Leishmania major Infections Infect. Immun., October 1, 2002; 70(10): 5715 - 5720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Kim, R. Manoukian, R. Yeh, S. M. Silbiger, D. M. Danilenko, S. Scully, J. Sun, M. L. DeRose, M. Stolina, D. Chang, et al. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production Blood, September 18, 2002; 100(7): 2330 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aseffa, A. Gumy, P. Launois, H. R. MacDonald, J. A. Louis, and F. Tacchini-Cottier The Early IL-4 Response to Leishmania major and the Resulting Th2 Cell Maturation Steering Progressive Disease in BALB/c Mice Are Subject to the Control of Regulatory CD4+CD25+ T Cells J. Immunol., September 15, 2002; 169(6): 3232 - 3241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Compton and J. P. Farrell CD28 Costimulation and Parasite Dose Combine to Influence the Susceptibility of BALB/c Mice to Infection with Leishmania major J. Immunol., February 1, 2002; 168(3): 1302 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Raju, B. A. Rabinovich, L. G. Radvanyi, D. Spaner, and R. G. Miller A central role for IL-2 in fate determination of mature T cells--I: role in determining the Th1/Th2 profile in primary T cell cultures Int. Immunol., December 1, 2001; 13(12): 1453 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. M. Padigel, P. J. Perrin, and J. P. Farrell The Development of a Th1-Type Response and Resistance to Leishmania major Infection in the Absence of CD40-CD40L Costimulation J. Immunol., November 15, 2001; 167(10): 5874 - 5879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Heinzel and R. M. Rerko Cure of Progressive Murine Leishmaniasis: Interleukin 4 Dominance Is Abolished by Transient CD4+ T Cell Depletion and T Helper Cell Type 1-selective Cytokine Therapy J. Exp. Med., June 21, 1999; 189(12): 1895 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Elloso and P. Scott Expression and Contribution of B7-1 (CD80) and B7-2 (CD86) in the Early Immune Response to Leishmania major Infection J. Immunol., June 1, 1999; 162(11): 6708 - 6715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Castro, T. K. Sengupta, D. C. Ruiz, E. Yang, and L. B. Ivashkiv IL-4 Selectively Inhibits IL-2-Triggered Stat5 Activation, But Not Proliferation, in Human T Cells J. Immunol., February 1, 1999; 162(3): 1261 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Alexander, G. H. Coombs, and J. C. Mottram Leishmania mexicana Cysteine Proteinase-Deficient Mutants Have Attenuated Virulence for Mice and Potentiate a Th1 Response J. Immunol., December 15, 1998; 161(12): 6794 - 6801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Heinzel, R. M. Rerko, A. M. Hujer, and R. A. Maier Jr. Increased Capacity for Interleukin-2 Synthesis Parallels Disease Progression in Mice Infected with Leishmania major Infect. Immun., September 1, 1998; 66(9): 4537 - 4540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Ahuja, S. Mummidi, H. L. Malech, and S. K. Ahuja Human Dendritic Cell (DC)-Based Anti-Infective Therapy: Engineering DCs to Secrete Functional IFN-{gamma} and IL-12 J. Immunol., July 15, 1998; 161(2): 868 - 876. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
